Report cover image

Asia Pacific Fabry Disease Treatment Market Size, Share, & Industry Analysis Report By Route of Administration (Intravenous Route and Oral Route), By Therapy, By Distribution Channel, By Country – Market Forecast, 2025–2034

Publisher Polaris Market Research & Consulting LLP
Published Jun 01, 2025
Length 129 Pages
SKU # PLRS20198910

Description

The asia pacific Fabry’s disease treatment market size is expected to reach USD 1,088.17 million by 2034, according to a new study by Polaris Market Research. The report “Asia Pacific Fabry’s Disease Treatment Market Size, Share, & Industry Analysis Report: By Route of Administration (Intravenous Route and Oral Route), By Therapy, By Distribution Channel, and By Country – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The Asia Pacific Fabry’s disease treatment market represents a rapidly evolving segment within the rare disease therapeutics landscape, driven by increased clinical awareness, expanding diagnostic infrastructure, and rising accessibility to advanced biologics. The market encompasses a range of therapeutic approaches aimed at managing lysosomal alpha-galactosidase A enzyme deficiency, which underpins the pathophysiology of Fabry’s disease. Accelerated efforts in early diagnosis through newborn screening programs and targeted genetic testing are supporting timely therapeutic intervention, improving long-term patient outcomes. Increasing pharmaceutical R&D activity focused on enzyme replacement therapy (ERT), substrate reduction therapy (SRT), and gene-based modalities is pushing the development pipeline forward.

Strategic pricing reforms and the inclusion of Fabry’s therapies in national rare disease programs are enabling broader treatment access. Additionally, the availability of oral formulations and home-infusion protocols is enhancing patient adherence and quality of life, driving sustained treatment uptake. A growing focus on developing next-generation recombinant enzymes and chaperone therapies tailored for Asian genetic variants is reinforcing innovation in this space. The increasing integration of real-world evidence (RWE) to support regulatory and reimbursement pathways reflects a maturing market outlook. Technological advances in digital health tools are enabling longitudinal monitoring and improved disease management.

Asia Pacific Fabry’s Disease Treatment Market Report Highlights

By route of administration, in 2024, the intravenous route segment accounted for the largest share. The dominance of this segment is attributed to the established use of enzyme replacement therapy (ERT), which is typically administered intravenously.

Based on therapy, in 2024, the enzyme replacement therapy (ERT) segment accounted for the largest share. This dominance is largely attributed to the extensive clinical evidence supporting ERT in managing both classic and atypical Fabry’s manifestations.

The China Fabry’s disease treatment market accounted for the largest share. This growth is driven by rising awareness among healthcare professionals and patients, improved diagnostic capabilities, and an increasing number of patients being identified and treated.

A few key players include Amicus Therapeutics, Inc.; CANbridge Life Sciences Ltd.; Chiesi Farmaceutici S.p.A.; Idorsia Pharmaceuticals Ltd.; ISU ABXIS Co., Ltd.; JCR Pharmaceuticals Co., Ltd.; Protalix Biotherapeutics Inc.; Sangamo Therapeutics, Inc.; Sanofi; and Takeda Pharmaceutical.

Polaris Market Research has segmented the Asia Pacific Fabry’s disease treatment market report on the basis of route of administration, therapy, distribution channel, and region:

By Route of Administration Outlook (Revenue, USD Million, 2020–2034)

Intravenous Route

Oral Route

By Therapy Outlook (Revenue, USD Million, 2020–2034)

Enzyme Replacement Therapy (ERT)

Substrate Reduction Therapy (SRT)

Others

By Distribution Channel Outlook (Revenue, USD Million, 2020–2034)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Country Outlook (Revenue, USD Million, 2020–2034)

China

Japan

India

South Korea

Taiwan

Indonesia

Malaysia

Pakistan

Rest of Asia Pacific

Table of Contents

129 Pages
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Asia Pacific Fabry’s Disease Treatment Market Insights
4.1. Asia Pacific Fabry’s Disease Treatment Market – Market Snapshot
4.2. Asia Pacific Fabry’s Disease Treatment Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Increasing Pharmaceutical R&D Investments
4.2.1.2. Expansion of Medical Tourism
4.2.2. Restraints and Challenges
4.2.2.1. Shortage of Skilled Personal
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Asia Pacific Fabry’s Disease Treatment Market Trends
4.6. Value Chain Analysis
5. Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration
5.1. Key Findings
5.2. Introduction
5.2.1. Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
5.3. Intravenous Route
5.3.1. Asia Pacific Fabry’s Disease Treatment Market, by Intravenous Route, by Country, 2020-2034 (USD Million)
5.4. Oral Route
5.4.1. Asia Pacific Fabry’s Disease Treatment Market, by Oral Route, by Country, 2020-2034 (USD Million)
6. Asia Pacific Fabry’s Disease Treatment Market, by Therapy
6.1. Key Findings
6.2. Introduction
6.2.1. Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
6.3. Enzyme Replacement Therapy (ERT)
6.3.1. Asia Pacific Fabry’s Disease Treatment Market, by Enzyme Replacement Therapy (ERT), by Country, 2020-2034 (USD Million)
6.4. Substrate Reduction Therapy (SRT)
6.4.1. Asia Pacific Fabry’s Disease Treatment Market, by Substrate Reduction Therapy (SRT), by Country, 2020-2034 (USD Million)
6.5. Others
6.5.1. Asia Pacific Fabry’s Disease Treatment Market, by Others, by Country, 2020-2034 (USD Million)
7. Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel
7.1. Key Findings
7.2. Introduction
7.2.1. Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
7.3. Hospital Pharmacies
7.3.1. Asia Pacific Fabry’s Disease Treatment Market, by Hospital Pharmacies, by Country, 2020-2034 (USD Million)
7.4. Retail Pharmacies
7.4.1. Asia Pacific Fabry’s Disease Treatment Market, by Retail Pharmacies, by Country, 2020-2034 (USD Million)
7.5. Online Pharmacies
7.5.1. Asia Pacific Fabry’s Disease Treatment Market, by Online Pharmacies, by Country, 2020-2034 (USD Million)
8. Asia Pacific Fabry’s Disease Treatment Market, by Country
8.1. Key Findings
8.2. Introduction
8.3. Asia Pacific Fabry’s Disease Treatment Market – Asia Pacific
8.3.1. Asia Pacific: Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
8.3.2. Asia Pacific: Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
8.3.3. Asia Pacific: Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
8.3.4. Asia Pacific Fabry’s Disease Treatment Market – China
8.3.4.1. China: Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
8.3.4.2. China: Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
8.3.4.3. China: Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
8.3.5. Asia Pacific Fabry’s Disease Treatment Market – India
8.3.5.1. India: Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
8.3.5.2. India: Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
8.3.5.3. India: Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
8.3.6. Asia Pacific Fabry’s Disease Treatment Market – Malaysia
8.3.6.1. Malaysia: Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
8.3.6.2. Malaysia: Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
8.3.6.3. Malaysia: Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
8.3.7. Asia Pacific Fabry’s Disease Treatment Market – Japan
8.3.7.1. Japan: Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
8.3.7.2. Japan: Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
8.3.7.3. Japan: Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
8.3.8. Asia Pacific Fabry’s Disease Treatment Market – Indonesia
8.3.8.1. Indonesia: Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
8.3.8.2. Indonesia: Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
8.3.8.3. Indonesia: Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
8.3.9. Asia Pacific Fabry’s Disease Treatment Market – South Korea
8.3.9.1. South Korea: Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
8.3.9.2. South Korea: Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
8.3.9.3. South Korea: Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
8.3.10. Asia Pacific Fabry’s Disease Treatment Market – Australia
8.3.10.1. Australia: Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
8.3.10.2. Australia: Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
8.3.10.3. Australia: Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
8.3.11. Asia Pacific Fabry’s Disease Treatment Market – Rest of Asia Pacific
8.3.11.1. Rest of Asia Pacific: Asia Pacific Fabry’s Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
8.3.11.2. Rest of Asia Pacific: Asia Pacific Fabry’s Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
8.3.11.3. Rest of Asia Pacific: Asia Pacific Fabry’s Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
10.1. Amicus Therapeutics, Inc.
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Recent Development
10.2. CANbridge Life Sciences Ltd.
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Recent Development
10.3. Chiesi Farmaceutici S.p.A.
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Recent Development
10.4. Idorsia Pharmaceuticals Ltd.
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Recent Development
10.5. ISU ABXIS Co., Ltd.
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Recent Development
10.6. JCR Pharmaceuticals Co., Ltd.
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Recent Development
10.7. Protalix Biotherapeutics Inc.
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Recent Development
10.8. Sangamo Therapeutics, Inc.
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Recent Development
10.9. Sanofi
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Recent Development
10.10. Takeda Pharmaceutical
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Recent Development

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us